Company / EPS (Diluted)
Cytokinetics EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$6.54
FY2025
5-year range
-$6.54 / -$1.97
FY2021-FY2025
Trend
-51.0%
vs FY2024
Sector context
#190 of 204
Health Care
What the data says
Among 204 Health Care companies, Cytokinetics is in the bottom 7% for eps (diluted). EPS (Diluted) has declined for 3 consecutive years, from $-1.97 in FY2022 to $-6.54 in FY2025.
Based on SEC 10-K filings.
-6.54 in FY2025.
Declined from $-2.80 to $-6.54 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 204This company -$6.54 Sector average -$0.89
▼
-638.0% below sector average
Key checks
Key Insights
- Cytokinetics's eps (diluted) has declined for 3 consecutive years.
- In FY2025, eps (diluted) decreased 51.0% year-over-year.
- Ranks #190 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.54 | -51.0% |
| FY2024 | -$4.33 | -54.6% |
| FY2023 | -$2.80 | -42.1% |
| FY2022 | -$1.97 | +29.6% |
| FY2021 | -$2.80 | -42.1% |
| FY2020 | -$1.97 | +6.6% |
| FY2019 | -$2.11 | -8.2% |
| FY2018 | -$1.95 | +24.7% |
| FY2017 | -$2.59 | -764.1% |
| FY2016 | $0.39 | +140.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026